Serono S.A. had at least 14 compounds in development in 2006 prior to its acquisition by Merck KGaA (Xetra:MRK). Only three remain, and only two of those have advanced. The rest were discontinued, out-licensed or returned to the partner. Sources: BCIQ: BioCentury Online Intelligence; Merck KGaA

Serono drug

Indication

2006 status

2012 status

Partner

Active programs

Kuvan sapropterin dihydrochloride

Phenylketonuria (PKU)

Ph III

Mkt in EU

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)